<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        33-5286-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MODZAL 15MG/3ML INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MIDAZOLAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        36.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05CD08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Modzal</strong> 1 mg/ml &amp; 5 mg/ml Solution for Injection contains Midazolam. Midazolam belongs to a group of medicines known as benzodiazepines (sedatives).</p><p>&nbsp;</p><p>It is a short acting medicine that is used to induce sedation (a very relaxed state of calm, drowsiness or sleep) and relieves anxiety and muscle tension.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conscious &nbsp;sedation (an awake &nbsp;but &nbsp;very relaxed &nbsp;state &nbsp;of calm &nbsp;or drowsiness &nbsp;during &nbsp;a &nbsp;medical &nbsp;test &nbsp;or</p><p>procedure) in adults and children</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sedation of adults and children, in intensive care units.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaesthesia in adults, used alone or with other medicines.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Premedication medicine used to cause relaxation, calm and drowsiness before an anaesthetic) in adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Modzal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to midazolam, group of medicines known as benzodiazepines or any</p><p>other ingridients in the midazolam solution for injection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe difficulties with your breathing and that you are to undergo conscious sedation.</p><p>You must not be given midazolam if any of the above applies to you. If you are not sure, talk to your doctor or nurse before you are given this medicine.</p><p>&nbsp;</p><p>Take Special Care with Modzal</p><p>Midazolam should be used only when age- and size-appropriate resuscitation facilities are available. Administration of midazolam may depress myocardial contractility (ability of heart muscle to contract) and cause apnoea (pauses in breathing). Severe cardio respiratory adverse events have occurred on rare occasions. These have included respiratory depression, apnea, respiratory and/or cardiac arrest. To avoid such incidents, the injection should be given slowly and the dose should be as low as possible.</p><p>&nbsp;</p><p>Special care needs to be taken if midazolam is used in babies or children. Let your doctor know if your child has a cardiovascular disease. Your child will be carefully monitored and the dose will be adjusted specially.</p><p>&nbsp;</p><p>Patients under 6 months old in sedation in Intensive Care Unit are more likely to develop breathing problems, so they will be dosed very gradually and their breathing and oxygen levels observed.</p><p>&nbsp;</p><p>When midazolam is given as a premedication, you will be checked closely to how you respond and to ensure you have received the right dose as the sensitivity varies depending of the patient.</p><p>The use of midazolam is not recommended in neonates and children up to 6 months of age.</p><p>Paradoxical reactions and anterograde amnesia (loss of memory for recent events) have been reported to occur with midazolam (see section 4. Possible Side Effects).</p><p>&nbsp;</p><p>&nbsp;</p><p>Before midazolam is given, let your doctor or nurse know if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are over 60 years of age</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a long term &nbsp;illness or are debilitated &nbsp;(for example, chronic respiratory problems, renal, &nbsp;hepatic or cardiac disorders).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a myasthenia gravis (neuromuscular disease characterized by a muscle weakness).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of alcohol or drug abuse.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking any other medicines including those not prescribed by your doctor (for more information see section &lsquo;Using other medicines&rsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or think being pregnant.</p><p>If any of the above applies to you, or if you are not sure, talk to your doctor or nurse before you are given midazolam.</p><p>&nbsp;</p><p>Long term treatment</p><p>If you receive long-term midazolam, you may become tolerant (midazolam becomes less effective) or you may be become dependent upon this medicine.</p><p>&nbsp;</p><p>After treatment for a long time (such as in an intensive care unit) the following withdrawal symptoms may occur: headaches, muscle pain, anxiety, tension, restlessness, confusion, irritability, inability to sleep, mood changes, hallucinations and convulsions. Your doctor will reduce your dose gradually to avoid these effects happening to you.</p><p>&nbsp;</p><p>Using other medicines:</p><p>Please tell your doctor if you &nbsp;are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal medicines.</p><p>&nbsp;</p><p>This is extremely important, as using more than one medicine at the same time can strengthen or weaken the effect of the medicines involved.</p><p>&nbsp;</p><p>In particular, tell your doctor or nurse if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tranquilisers (for anxiety or to help you sleep)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypnotics (medicines to make you sleep)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sedatives (to make you feel calm or sleepy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antidepressants (medicines for depression)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; narcotic analgesics (very strong pain killers)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antihistamines (used to treat allergies)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp; treat&nbsp;&nbsp;&nbsp; fungal&nbsp;&nbsp; infections&nbsp;&nbsp; (ketoconazole,&nbsp;&nbsp; voriconazole,&nbsp;&nbsp;&nbsp; fluconazole,&nbsp;&nbsp;&nbsp; itraconazole, posaconazole)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; macrolide antibiotics (such as erythromycin or clarithromycin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diltiazem (used to treat high blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for HIV called protease inhibitors (such as saquinavir)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atorvastatin (used to treat high cholesterol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (used to treat mycobacterial infections such as tuberculosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the herbal medicine St. John&rsquo;s Wort.</p><p>If any of the above apply to you, or if you are not sure, talk to your doctor or nurse before you are given midazolam.</p><p>Concomitant use of Midazolam and opioids (strong pain killers, medicines for substitution therapy and some cough medicines) increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible.</p><p>&nbsp;</p><p>However if your doctor does prescribe Midazolam together with opioids the dose and duration of concomitant treatment should be limited by your doctor.</p><p>&nbsp;</p><p>Please tell your doctor about all opioid medicines you are taking, and follow your doctor&rsquo;s dose recommendation closely. It could be helpful to inform friends&nbsp; or relatives&nbsp; to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.</p><p>&nbsp;</p><p>&nbsp;</p><p>Operations</p><p>If &nbsp;you &nbsp;are &nbsp;going to &nbsp;have an inhaled &nbsp;anaesthetic &nbsp;(one that &nbsp;you &nbsp;breathe &nbsp;in) &nbsp;for &nbsp;an operation or for dental treatment, it is important to tell your doctor or dentist that you have been given midazolam.</p><p>&nbsp;</p><p>Using midazolam with food and drink</p><p>While you &nbsp;are using midazolam &nbsp;you must not drink any alcohol, since alcohol can markedly increase the sedative effect of midazolam.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding and fertility:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or breast-feeding or think you may be pregnant, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will decide if should be given this medicine or not. During late pregnancy, labour or caesarean section, you might have an inhalation risk and your baby might have&nbsp; an irregular heart beat, hypotonia (state of low muscle tone), feeding difficulties, a low body temperature and respiratory depression (difficulty in breathing).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have passed through prolonged treatment during last phase of pregnancy with this medicine, your baby may develop physical dependence and risk of withdrawal symptoms after birth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Midazolam may pass into breast milk, therefore, if you are breast feeding you should not do so for 24 hours after receiving this medicine.</p><p>&nbsp;</p><p>Driving and using machines:</p><p>This medicine may make you sleepy, forgetful or affect your concentration and co-ordination.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not drive while taking this medicine until you know how it affects you. This may affect your performance at skilled tasks, e.g. driving or operating machinery. After midazolam administration you should not drive a vehicle or operate a machine until completely recovered. Your doctor should advise you when you can start these again.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should always be accompanied to home by a responsible adult after your treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is an offence to drive if this medicine affects your ability to drive.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, you would not be committing an offence if:</p><p>o&nbsp;&nbsp; The medicine has been prescribed to treat a medical or dental problem and</p><p>o&nbsp;&nbsp; You &nbsp;have &nbsp;taken &nbsp;it &nbsp;according to &nbsp;the &nbsp;instructions &nbsp;given &nbsp;by the &nbsp;prescriber &nbsp;or &nbsp;in the &nbsp;information</p><p>provided with the medicine and</p><p>o&nbsp;&nbsp; It was not affecting your ability to drive safely</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>Important information about some of the ingredients of midazolam solution for injection</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose i.e. essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Modzal</strong> should be administered only by experienced physicians in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the recognition and management of expected adverse events.</p><p>&nbsp;</p><p>Dosage and route of administration</p><p>Your doctor will decide on a suitable dose for you. Doses vary considerably and will depend on the planned</p><p>treatment and the sedation required. Your weight, age, general condition of health, concomitant medication, response to the drug and whether other medicines are required at the same time will also influence the dose that you receive.</p><p>&nbsp;</p><p>If &nbsp;you &nbsp;are &nbsp;to &nbsp;receive &nbsp;strong painkillers, &nbsp;you &nbsp;will receive &nbsp;these &nbsp;first &nbsp;and &nbsp;then&nbsp; have &nbsp;your &nbsp;midazolam &nbsp;dose adjusted specially for you.</p><p>&nbsp;</p><p><strong>Modzal</strong> is &nbsp;given slowly,&nbsp; by injection into &nbsp;a vein (intravenously), by a drip &nbsp;(infusion),&nbsp; injection into&nbsp; a muscle (intramuscular) or via rectal administration.</p><p>You should always be taken home by a responsible adult after your treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Children and babies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In infants and babies under 6 months of age midazolam is only recommended for sedation in intensive care units. The dose will be given gradually into a vein.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children 12 years and under will usually be given midazolam into a vein. When midazolam is used for premedication (to cause relaxation, calm and drowsiness before an anaesthetic) it may be given into the back passage (rectum).</p><p>&nbsp;</p><p>If you use more Modzal &nbsp;than you should</p><p>Your medicine will be given by a doctor or nurse.</p><p>If you accidentally got an overdose, this could lead to sleepiness, ataxia (in coordination &nbsp;of &nbsp;voluntary muscular action), dysarthria (speech disorder) and nystagmus (involuntary eye movements), loss of reflexes, apnoea (suspension of breathing), hypotension (low blood pressure), cardio respiratory depression and in rare cases coma. Overdose may require intense vital sign monitoring and symptomatic treatment of cardio respiratory effects and use of benzodiazepine antagonist.</p><p>&nbsp;</p><p>If you stop using Modzal</p><p>Sudden discontinuation of treatment can be accompanied by withdrawal symptoms such as headache, muscular pain, anxiety, tension, restlessness, confusion, mood swings, hallucinations &amp; convulsions, rebound insomnia, irritability and convulsions. Since the risk of withdrawal symptoms occurring is greater if treatment is discontinued abruptly, dose should be reduced gradually when treatment is being discontinued.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like &nbsp;all &nbsp;medicines &nbsp;midazolam &nbsp;can &nbsp;cause &nbsp;side &nbsp;effects, &nbsp;although &nbsp;not &nbsp;everybody gets &nbsp;them. &nbsp;The &nbsp;following undesirable effects have been reported (frequency not known).</p><p>&nbsp;</p><p>Stop having midazolam and see a doctor straight away if you notice any of the following side effects. They can be life-threatening and you may need urgent medical treatment:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic shock (a life-threatening allergic reaction). Signs may include a sudden rash, itching or lumpy rash (hives) and swelling of the face, lips, tongue or other parts of the body. You may also have shortness of breath, wheezing or trouble breathing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart &nbsp;attack &nbsp;(cardiac &nbsp;arrest). &nbsp;Signs &nbsp;may &nbsp;include &nbsp;chest &nbsp;pain &nbsp;which &nbsp;may &nbsp;spread &nbsp;to &nbsp;your &nbsp;neck &nbsp;and shoulders and down your left arm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing problems or complications (sometimes causing the breathing to stop).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choking and sudden blockage of the airway (laryngospasm).</p><p>&nbsp;</p><p>Life-threatening side effects are more likely to occur in adults over 60 years of age and those who already have breathing difficulties or heart problems, particularly if the injection is given too fast or at a high dose.</p><p>&nbsp;</p><p>Other possible side effects:</p><p>&nbsp;</p><p>Immune System disorders:</p><p>General allergic reactions (skin reactions, heart and blood system reactions, wheezing)</p><p>Psychiatric disorders:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; euphoria (an excessive feeling of happiness or excitement)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucinations (seeing and possibly hearing things that are not really there)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hostility, rage or aggression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excitement</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drug dependence, abuse.</p><p>&nbsp;</p><p>Nervous system disorders :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness and prolonged sedation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced alertness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty co-ordinating muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (convulsions) in premature infants and new-born babies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; temporary memory loss. How long this lasts depends on how much midazolam you were given. You may experience this after your treatment. In isolated cases this has been prolonged (lasted for a long time).</p><p>&nbsp;</p><p>Cardiac and Vascular disorders :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow heart rate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the face and neck (flushing), fainting or headache.</p><p>&nbsp;</p><p>Gastrointestinal disorders:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth.</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (lumpy rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchiness.</p><p>&nbsp;</p><p>Musculoskeletal and connective tissue disorders:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasms and muscle tremors (shaking of your muscles that you cannot control).</p><p>&nbsp;</p><p>&nbsp;</p><p>General disorders and administration site conditions :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots or pain at the injection site.</p><p>&nbsp;</p><p>Injury Poisoning and Procedural Complications:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients taking benzodiazepine medicines are at risk of falling and breaking bones. This risk is increased in the elderly and those taking other sedatives (including alcohol).</p><p>&nbsp;</p><p><strong>To reports any side effect(s): </strong></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-The National Pharmacovigilance and Drug Safety Centre (NPC) :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use midazolam after the expiry date (EXP) which is stated on the carton and ampoule. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C, protect from light..</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The product is for single use and any remaining solution should be discarded.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use <strong>Modzal</strong> solution for injection or infusion if container is found leaking, solution is not clear with visible particles or any discoloration of the solution.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask &nbsp;your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient is midazolam (as midazolam hydrochloride).</p><p>&nbsp;</p><p>For 1 mg/ml</p><p>Each ml of solution for injection contains 1 mg of midazolam (as midazolam hydrochloride) Presentations&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 ml</p><p>Amount of midazolam&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 mg</p><p>&nbsp;</p><p>For 5 mg/ml</p><p>Each ml of solution for injection contains 5 mg of midazolam (as midazolam hydrochloride)</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Presentations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3 ml</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Amount of midazolam</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>15 mg</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>The other ingredients include water for injections, sodium chloride, sodium hydroxide ,hydrochloric acid &nbsp;and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Midazolam solution for injection is a clear colorless solution filled in a clear glass vial . 
Midazolam solution for injection is available in pack of 10 X 5 ml vials  for 1 mg/ml formulation.
    Midazolam solution for injection is available in pack of 5 X 3ml, vials for 5 mg/ml formulation.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi &ndash; Riyadh-kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                08/2018.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>مودزال</strong> عبارة&nbsp; عن محلول دواء معلق 1 ملغ/مللتر و 5 ملغ/مللتر للحقن يحتوي على الميدازولام. ينتمي الميدازولام إلى مجموعة من الأدوية المعروفة باسم البنزوديازيبين (المهدئات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">وهو دواء قصير المفعول يستخدم لإحداث تخدير (حالة من الاسترخاء والهدوء والنعاس الشديد أو النوم) ويخفف القلق وتوتر العضلات.</p><p dir="RTL">- &nbsp;&nbsp;التهدئة الواعية (في حالة يقظان ولكن باسترخاء وهدوء ونعاس شديد أثناء إجراء الفحص &nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp; الطبي أو الإجراء الطبي) عند البالغين والأطفال.</p><p dir="RTL">- &nbsp;&nbsp;تهدئة البالغين والأطفال، في وحدات العناية المركزة.</p><p dir="RTL">- &nbsp;&nbsp;تخدير البالغين، يستخدم لوحده أو مع أدوية أخرى.</p><p dir="RTL">- &nbsp;&nbsp;دواء مهدئ يستخدم لينتج عنه استرخاء وهدوء ونعاس قبل التخدير عند البالغين والأطفال.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم مودزال في الحالات التالية:</strong></p><p dir="RTL">- &nbsp;إذا كنت تعاني من حساسية (شديدة الحساسية) للميدازولام أو مجموعة الأدوية التي تعرف &nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp; باسم البنزوديازيبينات أو أي مكونات أخرى في محلول الميدازولام للحقن</p><p dir="RTL">- &nbsp;إذا كنت تعاني من صعوبات شديدة في التنفس وأنك ستخضع للتخدير الواعي.</p><p dir="RTL">يجب عدم إعطائك الميدازولام إذا كانت تنطبق عليك أي من الحالات السابقة. وإذا لم تكن متأكداً من ذلك، عليك التحدث مع طبيبك أو الممرضة قبل أن يتم إعطاؤك هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعطي عناية خاصة عند تناولك لدواء مودزال</strong></p><p dir="RTL">يستخدم الميدازولام فقط عندما تكون مرافق الإنعاش المناسبة للعمر والحجم متوفرة. حيث أن تناول ميدازولام قد يقلل من انقباض عضلة القلب (قدرة عضلة القلب على الانقباض) ويتسبب في انقطاع النفس (توقف في التنفس). وقد وقعت أعراض قلبية تنفسية جانبية خطيرة في حالات نادرة. وشملت هذه الأعراض صعوبة في التنفس، وانقطاع التنفس سكتة تنفسية و/أو قلبية. ولتجنب مثل هذه الأعراض ينبغي إعطاء الحقن ببطء وينبغي أن تكون الجرعة منخفضة بقدر الإمكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويجب توخي الحذر عند استخدام الميدازولام مع الأطفال الرضع أو الأطفال بشكل عام. ويجب إعلام طبيبك فيما إذا كان طفلك يعاني من مرض قلبي وعائي. وسيتم مراقبة طفلك بعناية وتعديل جرعته بشكل خاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المرضى الذين تقل أعمارهم عن 6 أشهر الذين هم تحت التخدير في وحدة العناية المركزة هم الأكثر عرضة للإصابة بمشاكل في التنفس، لذلك سيتم إعطاءهم الجرعات بشكل تدريجي للغاية وملاحظة التنفس لديهم وكذلك مستويات الأكسجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يتم إعطاء الميدازولام كتمهيد تخدير، سيتم فحصك عن كثب بخصوص كيفية الاستجابة وللتأكد من أنك قد تلقيت الجرعة المناسبة حيث أن الحساسية تختلف من مريض لآخر.</p><p dir="RTL">ولا ينصح باستخدام الميدازولام عند حديثي الولادة والأطفال حتى عمر 6 أشهر.</p><p dir="RTL">وقد تم الإبلاغ عن تفاعلات تناقضية وفقدان ذاكرة تقدمي (فقدان ذاكرة خاصة بالأحداث الأخيرة) تحدث مع تناول الميدازولام (انظر القسم 4، الآثار الجانبية المحتملة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل إعطاء الميدازولام، أخبر طبيبك أو الممرضة بخصوص ما يلي:</p><p dir="RTL">- &nbsp;إذا كان عمرك يزيد عن 60 عامًا</p><p dir="RTL">- &nbsp;إذا كنت مصاب بمرض طويل المدة أو اعتلال (على سبيل المثال، مشاكل تنفسية مزمنة أو &nbsp;</p><p dir="RTL">&nbsp;&nbsp; اضطرابات في الكلية أو كبدية أو قلبية).</p><p dir="RTL">- &nbsp;إذا كنت مصابا بالوهن العضلي الشديد (مرض عصبي عضلي يتميز بضعف العضلات).</p><p dir="RTL">- &nbsp;إذا كان لديك تاريخ في تعاطي الكحول أو تعاطي المخدرات.</p><p dir="RTL">- &nbsp;إذا تناولت أي أدوية أخرى بما في ذلك الأدوية التي لم يصفها لك الطبيب (لمزيد من &nbsp;</p><p dir="RTL">&nbsp;&nbsp; المعلومات، انظر قسم &quot;استخدام أدوية أخرى&quot;)</p><p dir="RTL">- &nbsp;إذا كانت المرأة حامل أو أنها تفكر في الحمل.</p><p dir="RTL">إذا كان أي من الحالات التي وردت أعلاه تنطبق عليك أو إذا لم تكن متأكداً من ذلك عليك باستشارة طبيبك أو ممرضتك قبل إعطاء الميدازولام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المعالجة طويلة الأجل</strong></p><p dir="RTL">إذا كنت تتناول الميدازولام لفترة طويلة الأجل، فقد تصبح أقل تأثرا بهذا الدواء (يصبح الميدازولام أقل فاعلية) أو قد تصبح معتمدًا على هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد العلاج لفترة طويلة (كما هو الحال في وحدة العناية المركزة) فقد تظهر أعراض الانسحاب التالية: الصداع،&nbsp; آلام العضلات، القلق، التوتر، التململ، الارتباك، التهيج، عدم القدرة على النوم، تغيرات في المزاج، الهلوسة والتشنجات. وسوف يخفض طبيبك من الجرعة التي تعطى لك بشكل تدريجي لتجنب أن تحدث لك مثل هذه الآثار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام أدوية أخرى:</strong></p><p dir="RTL">من فضلك أخبر طبيبك إذا كنت تتناول أو قد تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية والأدوية العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا أمر مهم للغاية، حيث أن استخدام أكثر من دواء واحد في نفس الوقت يمكن أن يقوي أو يضعف تأثير الأدوية المعنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك أو الممرضة إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المهدئات (للقلق أو لمساعدتك على النوم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المنومات (الأدوية التي تجعلك تنام)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المسكنات (لتجعلك تشعر بالهدوء أو النعاس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مضادات الاكتئاب (أدوية للاكتئاب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المسكنات المخدرة (مسكنات الألم القوية جدا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مضادات الهيستامين (تستخدم لعلاج الحساسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أدوية لعلاج الالتهابات الفطرية (كيتوكونازول، فوريكونازول، فلوكونازول، &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يتراكونازول، بوساكونازول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المضادات الحيوية ماكرولايد (مثل الاريثروميسين أو كلاريثرومايسين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ديلتيازيم (يستخدم لعلاج ارتفاع ضغط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أدوية لفيروس نقص المناعة البشرية وتسمى مثبطات الأنزيم البروتيني (مثل ساكوئينافير)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أتورفاستاتين (يستخدم لعلاج ارتفاع الكوليسترول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ريفامبيسين (يستخدم لعلاج التهابات الفطرية مثل السل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الأدوية العشبية سانت جونز ورت.</p><p dir="RTL">إذا كان لديك أي من الحالات المذكورة أعلاه أو إذا لم تكن متأكداً منها عليك التحدث مع طبيبك أو الممرضة قبل إعطائك دواء الميدازولام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن الاستخدام المتزامن للميدازولام والمواد الأفيونية (المسكنات القوية للألم، أدوية العلاج البديل وبعض أدوية السعال) يزيد من خطر النعاس وصعوبة التنفس (انخفاض في التنفس) والغيبوبة، وقد تكون مهددة للحياة. وبسبب هذا، فإن الاستخدام المتزامن يؤخذ في الاعتبار فقط عندما تكون خيارات العلاج الأخرى غير ممكنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ومع ذلك، فإذا وصف لك طبيبك دواء ميدازولام مع الأدوية الأفيونية، فإن الجرعة ومدة العلاج المصاحب يجب أن تحدد من قبل الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من فضلك أخبر طبيبك عن كل الأدوية الأفيونية التي تتناولها، واتبع توصيات الجرعة التي يصفها طبيبك عن كثب. وقد يكون من المفيد إعلام الأصدقاء أو الأقارب ليكونوا متنبهين للعلامات والأعراض المذكورة أعلاه. واتصل بطبيبك عند مواجهة مثل هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العمليات</strong></p><p dir="RTL">إذا كنت ستحصل على دواء مخدر عن طريق الاستنشاق (الذي تستنشقه) من أجل عملية جراحية أو لمعالجة الأسنان، فمن المهم أن تخبر طبيبك أو طبيب الأسنان أنك قد تناولت دواء ميدازولام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام الميدازولام مع الطعام والشراب</strong></p><p dir="RTL">أثناء استخدام الميدازولام، يجب ألا تشرب أي مشروبات كحولية لأن الكحول يمكن أن تزيد بشكل ملحوظ من التأثير المهدئ للميدازولام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتٍ حاملاً أو تقومي برضاعة طبيعية أو تعتقدي أنك حامل، اطلبي من طبيبك أو الصيدلي نصيحة قبل تناول هذا الدواء. وسيقرر طبيبك ما إذا كان يجب إعطائك هذا الدواء أم لا. وأثناء الحمل المتأخر أو الولادة أو الولادة القيصرية، فقد يكون لديك خطر من استنشاق الدواء حيث يمكن أن يحدث لطفلك ضربات قلب غير منتظمة ونقص توتر (حالة انخفاض توتر العضلات) وصعوبات في التغذية وانخفاض في درجة حرارة الجسم وانخفاض تنفسي (صعوبة في التنفس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وإذا كنتٍ قد مررتٍ بفترة علاج طويلة بهذا الدواء خلال المرحلة الأخيرة من الحمل، فقد يتطور لدى طفلك اعتماد بدني وخطر أعراض الانسحاب بعد الولادة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد ينتقل دواء الميدازولام إلى حليب الأم، لذلك إذا كنت تقومين بالرضاعة الطبيعية فلا يجب عليك القيام بالإرضاع لمدة 24 ساعة بعد تلقي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p dir="RTL">قد يجعلك هذا الدواء تشعر بالنعاس أو كثير النسيان أو يؤثر على تركيزك ورتابتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقوم بقيادة السيارات أثناء تناول هذا الدواء حتى تعرف مدى تأثير ذلك عليك. وقد يؤثر هذا على أدائك في المهام التي تتطلب مهارة، على سبيل المثال، قيادة السيارات أو تشغيل الآلات. وبعد تناول دواء الميدازولام يجب عليك عدم قيادة المركبات أو تشغيل الآلات حتى تتعافى تمامًا. ويجب أن ينصحك طبيبك ويخبرك عن متى يكون بإمكانك القيام بمثل هذه المهام مرة أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويجب أن يصاحبك وبشكل دائم شخص بالغ راشد في المنزل بعد العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وفي حال أن هذا الدواء يؤثر على قدرتك على القيادة فإن ممارسة القيادة تعتبر مخالفة جسيمة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ولكن، لا تعتبر أنك ترتكب مخالفة إذا:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تم وصف الدواء لعلاج مشكلة طبية أو لعلام الأسنان</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تناولت الدواء وفقا للتعليمات التي قدمها لك الواصف أو في المعلومات &nbsp;</p><p dir="RTL">&nbsp; المقدمة مع الدواء و</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;كان الدواء لم يؤثر على قدرتك على القيادة بأمان</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي إذا لم تكن متأكدًا ما إذا كان بإمكانك القيادة بشكل آمن أثناء تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة حول بعض مكونات محلول الميدازولام للحقن</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا المنتج الطبي على أقل من 1 ملي مول صوديوم (23 ملغ) في الجرعة أي &quot;خالٍ من الصوديوم&quot; بشكل جوهري.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يتم إعطاء دواء <strong>مودزال </strong>فقط من قبل الأطباء ذوي الخبرة وفي بيئة مجهزة بالكامل لرصد ولدعم وظيفة الجهاز التنفسي والقلب والأوعية الدموية ووجود أشخاص مدربين على وجه التحديد في إدراك وإدارة الأحداث السلبية المتوقعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة وطريقة الإعطاء</strong></p><p dir="RTL">سوف يقرر طبيبك الجرعة المناسبة لك. وتختلف الجرعات بشكل كبير وتعتمد على العلاج المقرر والتخدير المطلوب. وستتأثر الجرعة المقررة وستعتمد أيضا على وزنك، وعمرك، وحالتك الصحية العامة، والأدوية المصاحبة، والاستجابة للدواء، وما إذا كانت هناك حاجة إلى أدوية أخرى في نفس الوقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت ستحصل على مسكنات قوية للألم، فعليك تناول هذه المسكنات أولاً ومن ثم يتم تعديل الجرعة الخاصة بالميدازولام خصيصًا بما يناسب جرعة تلك المسكنات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء <strong>مودزال</strong> ببطء عن طريق الحقن في الوريد (عن طريق الوريد)&nbsp; بالتنقيط (تسريب)، وعن طريق الحقن في العضل (حقن عضلي) أو عبر المستقيم.</p><p dir="RTL">بعد تناولك لجرعة من دواء <strong>مودزال</strong> يجب دائما أن يعيدك لمنزلك شخص بالغ راشد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والرضع</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للرضع والأطفال دون سن 6 أشهر من العمر فإنه ينصح بإعطاء الميدازولام فقط للتخدير في وحدات العناية المركزة. وسيتم إعطاء الجرعة تدريجيا عن طريق الوريد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادة ما يعطى الأطفال في سن 12 سنة وما دون هذا السن فإنه عادة يتم إعطاءهم الميدازولام في الوريد. وعندما يستخدم الميدازولام لتمهيد التخدير (للتسبب في الاسترخاء والهدوء والنعاس قبل التخدير) يمكن إعطاؤه في الفتحة الشرجية (من خلال المستقيم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تستخدم دواء مودزال أكثر مما يجب</strong></p><p dir="RTL">فسيتم إعطاءك الدواء من قبل طبيب أو ممرضة.</p><p dir="RTL">إذا تم إعطاءك جرعة زائدة عن طريق الخطأ، فقد يؤدي ذلك إلى النعاس والرنح (في تنسيق العمل العضلي الطوعي) و الرُتَّة (عُسْرُ التَّلَفُّظ) و الرَأْرَأَة (حركات العين غير الطوعية) وفقدان المنعكسات وانقطاع التنفس (توقف التنفس) وانخفاض ضغط الدم (هبوط ضغط الدم) وانخفاض قلبي تنفسي وغيبوبة في حالات نادرة. قد تتطلب الجرعة الزائدة مراقبة مكثفة للعلامات الحيوية وعلاج أعراض الآثار تنفسية القلبية واستخدام مضاد البنزوديازيبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام مودزال</strong></p><p dir="RTL">يمكن أن يقترن التوقف المفاجئ للعلاج بأعراض الانسحاب مثل الصداع،&nbsp; آلام العضلات، القلق، التوتر، التململ، الارتباك، التهيج، عدم القدرة على النوم، تغيرات في المزاج، الهلوسة والتشنجات. وبما أن خطر حدوث أعراض الانسحاب يكون أكبر إذا توقف العلاج فجأة، فإنه يجب تقليل الجرعة تدريجيا عند التوقف عن العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء فعليك توجيهها لطبيبك أو للصيدلي أو للممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية يمكن أن يسبب دواء الميدازولام آثار جانبية، على الرغم من أن تلك الآثار لا تحصل لجميع من يتناول الميدازولام. وقد تم الإبلاغ عن الآثار غير المرغوب فيها التالية (تكرار غير معروف).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن تناول دواء الميدازولام وراجع الطبيب على الفور إذا لاحظت أي من الآثار الجانبية التالية. حيث أنها يمكن أن تكون مهددة للحياة وقد تحتاج إلى علاج طبي عاجل:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong>صدمة تأقية (رد فعل تحسسي يهدد الحياة). قد تتضمن العلامات طفحًا مفاجئًا أو حكة أو &nbsp;&nbsp;طفحًا متكتل (طفح جلدي) وتورم في الوجه أو الشفتين أو اللسان أو أجزاء أخرى من &nbsp;&nbsp;الجسم. وقد يكون لديك أيضا ضيق في التنفس أو الأزيز في التنفس أو مشاكل في التنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية (سكتة قلبية). قد تشمل العلامات آلام في الصدر قد تنتشر إلى الرقبة والكتفين وأسفل ذراعك الأيسر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس أو مضاعفات (تسبب أحيانا في توقف التنفس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاختناق والانسداد المفاجئ للمجرى التنفسي (تشنج الحنجرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المرجح أن تحدث الآثار الجانبية التي تهدد الحياة عند البالغين فوق سن الستين وأولئك الذين لديهم بالفعل مشاكل في التنفس أو مشاكل في القلب، خاصة إذا كان الحقن يتم بسرعة كبيرة أو بجرعة عالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المحتملة الأخرى:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>اضطرابات الجهاز المناعي:</em></strong></p><p dir="RTL">تفاعلات الحساسية عامة (تفاعلات جلدية، تفاعلات القلب ونظام الدورة الدموية، الأزيز)</p><p dir="RTL"><strong><em>اضطرابات نفسية:</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; النشوة (شعور مفرط بالسعادة أو الإثارة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; الهلوسة (رؤية وربما سماع أشياء ليست موجودة بالفعل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; الاهتياج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; العداء، الغضب أو الإثارة العدوانية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; الارتهان للمخدِّرات، التعسف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>اضطرابات الجهاز العصبي:</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; النعاس والتسكين لفترات طويلة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; قلة اليقظة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; صعوبة في تنسيق العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; نوبة (تشنجات) في الخدج والأطفال حديثي الولادة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; فقدان مؤقت للذاكرة. وتعتمد المدة التي يستغرقها هذا الأمر على مقدار الجرعة &nbsp;&nbsp;&nbsp;&nbsp; من دواء الميدازولام التي أعطيت للشخص. وقد تواجه هذا بعد معالجتك. وفي &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات معزولة طالت مدة هذه الحالة (استمرت لفترة طويلة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>اضطرابات القلب والأوعية الدموية:</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; بطئ معدل ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; احمرار في الوجه والرقبة (احمرار)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; الإغماء أو الصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>اضطرابات الجهاز الهضمي:</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>اضطرابات نسيج الجلد وتحت الجلد:</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; شرى (طفح متكتل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اضطرابات عضلية هيكلية والنسيج الضام:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات وارتعاشات في العضلات (اهتزاز العضلات بحيث لا تستطيع التحكم فيها).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الاضطرابات العامة وظروف موقع الإعطاء:</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; الضجر (التعب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; احمرار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; تورم في الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; تجلطات دم أو ألم في موقع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الإصابة بالتسمم والمضاعفات الإجرائية:</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; يكون المرضى الذين يتناولون أدوية البنزوديازيبين معرضون لخطر السقوط &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وكسر العظام. ويزداد هذا الخطر في كبار السن وأولئك الذين يتناولون المهدئات &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأخرى (بما في ذلك الكحول).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>للإبلاغ عن أي آثار جانبية:</em></strong></p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">- المركز الوطني للتيقظ الدوائي وسلامة الأدوية (NPC):</p><p dir="RTL">&bull; فاكس: + 966-11-205-7662</p><p dir="RTL">&bull; اتصال بـ المركز على هاتف رقم + 966-11-2038222 ، فرعي: 2371-2356-2353-2354-2334-2340.</p><p dir="RTL">&nbsp;&bull; هاتف مجاني: 19999</p><p dir="RTL">&bull; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&bull; موقع الويب: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم الميدازولام بعد تاريخ انتهاء الصلاحية الذي تم ذكره على العبوة الخارجية والأمبولة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحتفظ بدواء الميدازولام في درجة حرارة أعلى من 30 درجة مئوية، ويجب الاحتفاظ به بعيدا عن الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المنتج هو للاستخدام مرة واحدة ويجب التخلص من أي محلول متبقي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم محلول <strong>مودزال</strong> للحقن أو <strong>مودزال</strong> للتسريب في حالة ملاحظة وجود تسرب للدواء من الحاوية أو أن المحلول غير شفاف مع جزيئات مرئية أو أي تغير في لون المحلول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. حيث من شأن هذه التدابير أن تساعد على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي دواء مودزال:</strong></p><p dir="RTL">العنصر النشط هو الميدازولام (مثل: هيدروكلوريد الميدازولام).</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة <strong>لمودزال</strong> - دواء معلق 1 ملغ/مللتر</p><p dir="RTL">كل مللتر من محلول الحقن يحتوي على 1 ملغ من الميدازولام (مثل: هيدروكلوريد الميدازولام) تقديم 5 مللتر</p><p dir="RTL">الكمية من الميدازولام 5 ملغ</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة <strong>لمودزال</strong> - دواء معلق 5 ملغ/مللتر</p><p dir="RTL">يحتوي كل مللتر من محلول الحقن على 5 ملغ من الميدازولام (مثل هيدروكلوريد الميدازولام)</p><p dir="RTL">تقديم 3 مللتر</p><p dir="RTL">الكمية من الميدازولام 15 ملغ</p><p dir="RTL">وتشمل المكونات الأخرى: ماء للحقن، كلوريد الصوديوم، هيدروكسيد الصوديوم، حمض الهيدروكلوريك وماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محلول الميدازولام للحقن هو محلول عديم اللون شفاف معبأ في قارورة زجاجية شفافة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم توفير محلول الميدازولام للحقن في حزمة من 10 قوارير سعة كل منها 5 مللتر، بتركيبة 1 ملغ/مللتر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويتم توفير محلول الميدازولام للحقن في حزمة من 5 قوارير سعة كل منها 3 مللتر، بتركيبة 5 ملغ/مللتر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أم أس فارما السعودية - الرياض - المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في شهر أغسطس/2018.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Modzal 15mg/3ml solution for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vial contains 15mg of Midazolam as active substance.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults:</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Premedication before the induction of anesthesia (intramuscular administration).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Induction and maintenance of anesthesia. As an induction agent in inhalation anesthesia or as a sedative component in balanced anesthesia, including intravenous general anesthesia (intravenous injection, intravenous infusion).</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term sedation in intensive care units (i.v. administration as bolus injection or continuous infusion).</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Conscious sedation before diagnostic or surgical interventions with or without local anesthesia (intravenous administration).</p><p><u>Children:</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conscious sedation before diagnostic or surgical interventions with or without local anesthesia (i.v., i.m or rectal administration).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Premedication before induction of anesthesia (i.m or mainly rectal administration ).</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ataralgesia in combination with ketamine in children (intramuscular administration).</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-term sedation in intensive care units (intravenous injection as a bolus or continuous infusion).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Midazolam is a potent sedative that requires slow administration and an individualised dosage. The dose must be adapted to each case.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose titration is a mandatory recommendation to ensure the safe induction of the desired degree of sedation according to clinical need, physical status, age and comedication.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients over 60 years of age, critically ill patients, or patients belonging to a high-risk group, and in pediatric patients, the dosage must be determined with caution and careful regard for the specific characteristics of each patient.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intravenous injection must be given slowly (approximately 2.5 mg in 10 seconds for the induction of anesthesia and 1 mg in 30 seconds for conscious sedation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Onset of effect is approximately 2 minutes after the start of injection. Peak effect is achieved after approximately 5 to 10 minutes.</p><p>Standard dosages are provided in the table below. Additional details are provided in the text following the table.</p><p><strong>Table 1. Standard dosages </strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:747px"><tbody><tr><td><p dir="LTR"><strong>Indication</strong></p></td><td><p dir="LTR"><strong>Adults &lt;60 years</strong></p></td><td><p dir="LTR"><strong>Adults &ge;60 years / critically ill patients or those at high risk</strong></p></td><td><p dir="LTR"><strong>Children and adolescents</strong></p></td></tr><tr><td><p dir="LTR">Conscious sedation</p></td><td><p dir="LTR">i.v. Initial dose: 2&ndash;2.5 mg, Titration dose: 1 mg Total dose: 3.5&ndash;7.5 mg.</p></td><td><p dir="LTR">i.v. Initial dose: 0.5&ndash;1 mg, Titration dose: 0.5&ndash;1 mg Total dose: &le;3.5 mg .</p></td><td><p dir="LTR">i.v. 6 months &ndash; 5 years: Initial dose: 0.05&ndash;0.1 mg/kg BW</p><p dir="LTR">Total dose: &le;6 mg</p><p dir="LTR">i.v. 6&ndash;12 years: Initial dose: 0.025&ndash;0.05 mg/kg BW Total dose: &le;10 mg</p><p dir="LTR">i.v. 13&ndash;16 years: as for adults</p><p dir="LTR">Rectal administration &gt;6 months: 0.3&ndash;0.5 mg/kg BW</p><p dir="LTR">i.m. 1&ndash;15 years: 0.05&ndash;0.15 mg/kg BW.</p></td></tr><tr><td><p dir="LTR">Premedication before induction of anesthesia</p></td><td><p dir="LTR">i.v. 1&ndash;2 mg, repeated</p><p dir="LTR">i.m. 0.07&ndash;0.1 mg/kg BW</p></td><td><p dir="LTR">i.v. Initial dose: 0.5 mg Slow uptitration as needed</p><p dir="LTR">i.m. 0.025&ndash;0.05 mg/kg BW</p><p dir="LTR">&nbsp;</p></td><td><p dir="LTR">Rectal administration &gt;6 months: 0.3&ndash;0.5 mg/kg BW</p><p dir="LTR">i.m. 1&ndash;15 years: 0.08&ndash;0.2 mg/kg BW</p></td></tr><tr><td><p dir="LTR">Induction of anesthesia</p></td><td><p dir="LTR">i.v. 0.2 mg/kg BW (0.2&ndash;0.35 mg/kg BW without premedication)</p></td><td><p dir="LTR">i.v. 0.05&ndash;0.15 mg/kg BW (0.2 mg/kg BW without premedication)</p></td><td><p dir="LTR">Not indicated in children</p></td></tr><tr><td><p dir="LTR">Sedative component in combined anesthesia</p></td><td><p dir="LTR">i.v. intermittent doses of 0.03&ndash;0.1 mg/kg BW or continuous infusion of 0.03&ndash;0.1 mg/kg BW/h</p></td><td><p dir="LTR">i.v. Lower doses than recommended for adults &lt;60 years</p></td><td><p dir="LTR">Not indicated in children</p></td></tr><tr><td><p dir="LTR">Sedation in intensive care units</p></td><td><p dir="LTR">i.v. Initial dose: 0.03&ndash;0.3 mg/kg BW increasing by 1&ndash;2.5 mg increments Maintenance dose: 0.03&ndash;0.2 mg/kg BW/h</p></td><td><p dir="LTR">&nbsp;</p></td><td><p dir="LTR">i.v.</p><p dir="LTR">Gestational age &lt;32 weeks: 0.03 mg/kg BW/h</p><p dir="LTR">i.v.</p><p dir="LTR">Gestational age &gt;32 weeks up to 6 months: 0.06 mg/kg BW/h</p><p dir="LTR">i.v.</p><p dir="LTR">Age &gt;6 months: Initial dose: 0.05&ndash;0.2 mg/kg BW Maintenance dose: 0.06&ndash;0.12 mg/kg BW/h</p></td></tr></tbody></table><p>(BW: body weight; i.m.: intramuscular; i.v.: intravenous)</p><p>&nbsp;</p><p><strong>Conscious sedation </strong></p><p><strong>MODZAL&reg;</strong>&nbsp;is administered intravenously for conscious sedation before a diagnostic or surgical procedure. The dose must be individualized and titrated; the drug must not be administered by rapid or single bolus injection.</p><p>The onset of sedation may vary between individuals depending on the patient&rsquo;s physical status and the exact administration conditions (e.g. rate of administration, amount of dose). If necessary, subsequent doses may be administered according to individual need.</p><p>Special care is mandatory in conscious sedation in patients with respiratory disorders.</p><p><em>Adults</em></p><p>Intravenous <strong>MODZAL&reg;</strong>&nbsp;injection must be given slowly &ndash; at a rate of approximately 1 mg in 30 seconds.</p><p>In adults below the age of 60 years, the initial dose is 2 to 2.5 mg; this is administered 5 to 10 minutes before the beginning of the procedure. Further doses of 1 mg may be given as necessary. Mean total doses of 3.5 to 7.5 mg are generally administered. A total dose exceeding 5.0 mg is not generally necessary.</p><p>In adults over the age of 60 years, critically ill patients or high-risk patients, the initial dose must be reduced to 0.5&ndash;1 mg and administered 5&ndash;10 minutes before the start of the procedure. Further doses of 0.5&ndash;1 mg may be given as needed. Since maximum effect may be reached less rapidly in these patients, additional doses of Midazolam should be titrated very slowly and carefully.</p><p>A total dose exceeding 3.5 mg is not generally necessary.</p><p><em>Children</em></p><p><em>Intravenous administration </em></p><p><strong>MODZAL&reg;</strong>&nbsp;should be administered with slow dose titration until the desired clinical effect is achieved. The initial dose of <strong>MODZAL&reg;</strong>&nbsp;should be administered over 2 to 3 minutes. Waiting a further 2&ndash;5 minutes is then recommended to allow careful assessment of the sedative effect before beginning the procedure or administering a new dose. If further sedation appears necessary, continue to titrate the dose with small increments until the desired level of sedation is achieved. Under certain conditions, infants and children under 5 years of age require markedly higher doses than older children or adolescents.</p><p>- Infants <em>under 6 months of age:</em> In infants under 6 months of age, the risk of upper respiratory tract obstruction and hypoventilation is particularly high. For this reason, the use of <strong>MODZAL&reg;</strong>&nbsp;is not recommended for conscious sedation in infants under 6 months of age, except if the benefit outweighs the risks. In such cases, dose titration in small increments and close supervision are essential until clinical effect is achieved.</p><p>- Children <em>aged 6 months to 5 years:</em> Initial dose: 0.05 to 0.1 mg/kg. A total dose up to 0.6 mg/kg may prove necessary to achieve the desired effect; however, the total dose should not exceed 6 mg. Prolonged sedation and a risk of hypoventilation may occur with the administration of higher doses.</p><p>Children <em>aged 6 to 12 years:</em> Initial dose: 0.025 to 0.05 mg/kg. A total dose of up to 0.4 mg/kg (to a maximum of 10 mg) may prove necessary. Prolonged sedation and a risk of hypoventilation may occur with the administration of higher doses .</p><p>- Adolescents aged 13 to 16 years: The dose is identical to that in adults.</p><p><em>Rectal administration (in children &gt;6 months) </em></p><p>The total dose of <strong>MODZAL&reg;</strong>&nbsp;ranges from 0.3 to 0.5 mg/kg.</p><p>The total dose should be administered at once; repeated rectal administration should be avoided. Use in infants under 6 months of age is not recommended, as only limited data are available in this group of patients.</p><p><em>Intramuscular administration (children aged 1 to 15 years) </em></p><p>The recommended dose ranges from 0.05 to 0.15 mg/kg and administration should be performed 5&ndash;10 minutes before the start of the procedure. A total dose exceeding 10.0 mg is not generally necessary. This route of administration should only be used in exceptional cases. Rectal administration should be preferred as intramuscular injection can be painful.</p><p>Administration of midazolam solutions at concentrations exceeding 1 mg/ml in children whose body weight is under 15 kg is not recommended. Higher concentrations should be diluted to 1 mg/ml.</p><p><strong>Premedication before induction of anesthesia </strong></p><p>Premedication with <strong>MODZAL&reg;</strong>&nbsp;administered just before a procedure produces sedation (with drowsiness and anxiolysis) and decreases preoperative memory capacity. <strong>MODZAL&reg;</strong>&nbsp;can also be administered in combination with anticholinergics. For this indication, <strong>MODZAL&reg;</strong>&nbsp;should be administered intravenously or intramuscularly (by deep injection into a large muscle mass 20 to 60 minutes before induction of anesthesia) or in children preferably via rectal route. Close patient monitoring is mandatory after administration as response varies between individuals and symptoms of overdose may occur.</p><p><em>Adults</em></p><p>For preoperative sedation and to decrease memory of preoperative events, the recommended dose for ASA I/II adults under 60 years of age is 1&ndash;2 mg intravenously (repeat administration as required) or 0.07&ndash;0.1 mg/kg intramuscularly.</p><p>The dose must be reduced and individually adjusted when Midazolam is administered to adults over 60 years of age, critically ill patients or those at high risk. The recommended initial intravenous dose is 0.5 mg, which should be increased as required by slow dose titration. This should be followed by 2&ndash;3 minutes&rsquo; wait to allow careful assessment of the effect of dose augmentation. A dose of 0.025&ndash;0.05 mg/kg i.m. is recommended in the absence of narcotic coadministration. The usual dose is 2&ndash;3 mg.</p><p><em>Children</em></p><p><em>Rectal administration (children ˃ 6 months) </em></p><p>The total dose of <strong>MODZAL&reg;</strong>&nbsp;is generally 0.4 mg/kg (range: 0.3&ndash;0.5 mg/kg), which should be administered 20 to 30 minutes before induction of anesthesia.</p><p>Use in infants under 6 months of age is not recommended, as only limited data are available in this group of patients.</p><p><em>Intramuscular administration (children aged 1 to 15 years): </em></p><p>Since intramuscular injections can be painful, this route of administration should only be used in exceptional cases. Rectal administration should be preferred. However, <strong>MODZAL&reg;</strong>&nbsp;doses ranging from 0.08 to 0.2 mg/kg have proved effective and safe.</p><p>Children aged 1 to 15 years require proportionally higher doses relative to body weight than adults. It is recommended that <strong>MODZAL&reg;</strong>&nbsp;be administered by deep injection into a large muscle mass 30 to 60 minutes before induction of anesthesia.</p><p>In children less than 15 kg of body weight, midazolam solutions at concentrations higher than 1 mg/ml are not recommended. Higher concentrations should be diluted to 1 mg/ml.</p><p><strong>Induction of anesthesia</strong></p><p><em>Adults</em></p><p>When <strong>MODZAL&reg;</strong>&nbsp;is used to induce anesthesia before the administration of other anesthetics, individual response is variable. The dose should be titrated to the desired effect according to the patient&rsquo;s age and clinical status. When <strong>MODZAL&reg;</strong>&nbsp;is used before or in combination with other intravenous or inhalational agents for inducing anesthesia, the initial dose of the various drugs can be set much lower (25% of their initial dose may suffice).</p><p>The desired level of anesthesia is reached by stepwise titration. The initial intravenous dose of <strong>MODZAL&reg;</strong>&nbsp;must be administered slowly and in increments. Each dose increment, which must not exceed 5 mg, must be injected over 20 to 30 seconds. A 2-minute pause should be observed between injections to titrate the dose.</p><p><em>Adults under 60 years of age </em></p><p>- A dose of 0.2 mg/kg, administered intravenously over 20 to 30 seconds and followed by a 2-minute pause to evaluate the effect, generally suffices.</p><p>-In non-premedicated patients, higher doses (0.3&ndash;0.35 mg/kg) may prove necessary; these are administered intravenously over 20 to 30 seconds and are followed by a 2-minute pause to evaluate the effect. If necessary, to complete the induction of anesthesia, the patients concerned can be given increments of approximately 25% of the initial dose. To complete the induction of anesthesia, inhalation of volatile liquid anesthetics can also be used as an alternative. In the event of inadequate patient response, a total dose of up to 0.6 mg/kg can be used to induce anesthesia; however, doses as high as this may delay recovery.</p><p><em>Adults over 60 years of age and/or critically ill patients or those at high risk </em></p><p>- In non-premedicated patients, the lowest initial dose of 0.15&ndash;0.2 mg/kg is recommended.</p><p>- In premedicated patients, a dose of 0.05&ndash;0.15 mg/kg, administered intravenously over 20&ndash;30 seconds and followed by a 2-minute pause to evaluate the effect, generally suffices.</p><p><em>Children</em></p><p>The use of <strong>MODZAL&reg;</strong>&nbsp;to induce anesthesia is reserved for adults, as experience is very limited in children.</p><p><strong>Sedative component in combined anesthesia </strong></p><p><em>Adults</em></p><p>When used as a sedative component in combined anesthesia, <strong>MODZAL&reg;</strong>&nbsp;can be administered as a series of intermittent low doses (ranging from 0.03 to 0.1 mg/kg) or as a continuous intravenous infusion (range: 0.03&ndash;0.1 mg/kg/h), generally in combination with analgesics. Dose and dose range depend on individual patient response.</p><p>Adults over 60 years of age, critically ill patients or those at high risk require lower maintenance doses.</p><p><em>Children</em></p><p>The use of <strong>MODZAL&reg;</strong>&nbsp;as a sedative component in combined anesthesia is reserved for adults as experience in children is very limited.</p><p><strong>Sedation in intensive care units </strong></p><p>The desired level of sedation is reached by increasing the dose of <strong>MODZAL&reg;</strong>&nbsp;stepwise (dose titration). Continuous infusion or intermittent bolus injection are then performed depending on clinical need, physical status, age and comedication.</p><p><em>Adults</em></p><p>Administration of the initial intravenous dose (0.03&ndash;0.3 mg/kg) should be given slowly in increments. Each increment of 1&ndash;2.5 mg should be injected over 20 to 30 seconds. A 2-minute pause for dose titration should be observed between injections.</p><p>The initial dose should be reduced or even withdrawn in patients with hypovolemia, vasoconstriction or hypothermia.</p><p>When <strong>MODZAL&reg;</strong>&nbsp;is combined with very potent analgesics, these should be administered first in order to evaluate their sedative effect. The patient&rsquo;s level of sedation can then be increased without risk by titrating the dose of <strong>MODZAL&reg;</strong>.</p><p>Intravenous maintenance dose: The intravenous maintenance dose may range between 0.03 and 0.2 mg/kg/h. The maintenance dose should be reduced in patients with hypovolemia, vasoconstriction or hypothermia. If the patient&rsquo;s condition allows, the level of sedation should be regularly checked. In long-term sedation loss of effect may occur, requiring an increase in dose.</p><p><em>Children</em></p><p>Administration of midazolam solutions in concentrations exceeding 1 mg/ml is not recommended in neonates (whether pre- or full-term) or in children weighing less than 15 kg. Higher concentrations should be diluted to 1 mg/ml.</p><p><em>Infants under 6 months of age </em></p><p><strong>MODZAL&reg;</strong>&nbsp;should be administered as a continuous intravenous infusion.</p><p>- Preterm infants of gestational age &lt;32 weeks: initial dose: 0.03 mg/kg/h (0.5 &mu;g/kg/min).</p><p>- Infants of gestational age &gt;32 weeks to 6 months: initial dose: 0.06 mg/kg/h (1 &mu;g/kg/min).</p><p>Intravenous initial doses should not be administered. Instead the infusion rate can be increased for the first few hours until therapeutic plasma concentrations are reached. The infusion rate should be carefully monitored, in particular after the first 24 hours, to ensure that the lowest possible effective dose is administered and that the risk of accumulation is kept as low as possible.</p><p>Respiratory rate and oxygen saturation should be closely monitored.</p><p><em>Children aged &gt;6 months </em></p><p>In intubated and ventilated patients, an initial dose of 0.05&ndash;0.2 mg/kg should be administered slowly i.v. over at least 2&ndash;3 minutes to achieve the desired effect. <strong>MODZAL&reg;</strong>&nbsp;should not be given by rapid intravenous administration. The initial dose is followed by a continuous intravenous infusion of 0.06&ndash;0.12 mg/kg/h (1&ndash;2 &micro;g/kg/min) <strong>MODZAL&reg;</strong>. The rate of infusion can be increased or decreased (generally by 25% of the initial infusion rate or the rate chosen immediately afterwards); supplemental doses of <strong>MODZAL&reg;</strong>&nbsp;can be administered intravenously to augment or maintain the effect.</p><p>When initiating treatment with <strong>MODZAL&reg;</strong>&nbsp;infusion in patients with hemodynamic disorders, the usual initial dose should be initiated by titrating the dose in small increments and the patient should be monitored for hemodynamic instability (e.g. the development of hypotension). These patients are also at risk of Midazolam -induced respiratory depression; their respiratory rate and oxygen saturation must be closely monitored for that reason.</p><p><strong>Special dosage instructions </strong></p><p><em>Renal impairment </em></p><p>Patients with renal impairment are similar to healthy people in the pharmacokinetics of free midazolam.</p><p>However, &alpha;-hydroxymidazolam accumulation has been observed in patients with chronic renal disease. The clinical effect of midazolam may therefore be augmented and lead to prolonged sedation.</p><p><em>Hepatic impairment </em></p><p>Hepatic impairment delays the elimination of intravenously administered midazolam, leading to an increase in terminal half-life. This may enhance and prolong the clinical effect. The dose of midazolam required to achieve the desired effect may be lower and vital functions need to be closely monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MODZAL® should not be administered to patients hypersensitive to benzodiazepines or to any of the excipients listed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>MODZAL&reg;</strong>&nbsp;vials should only be used when the availability of resuscitation facilities appropriate to the patient&rsquo;s age and size can be guaranteed, as intravenous <strong>MODZAL&reg;</strong>&nbsp;administration may depress myocardial contractility and cause apnea. Severe cardiorespiratory adverse events, such as respiratory depression, apnea, and respiratory and/or cardiac arrest, have been observed in rare cases. The probability of such life-threatening events occurring is increased if the product is injected too rapidly or at too high a dose.</p><p>When conscious sedation is to be performed by a physician who is not an anesthetist, the mandatory recommendation is to check current guidelines concerning practice in this regard.</p><p><em>Premedication </em></p><p>When using midazolam for premedication, intensive patient monitoring is mandatory after administration since response may vary between individuals and symptoms of overdosage may occur.</p><p><em>High-risk patients </em></p><p>Caution is especially mandatory when administering <strong>MODZAL&reg; </strong>to patients in high-risk groups:</p><p>&bull; Patients over 60 years of age.</p><p>&bull; Critically ill patients.</p><p>&bull; Patients with organ dysfunction:</p><p>- Respiratory impairment</p><p>- Renal impairment</p><p>- Hepatic impairment</p><p>- Cardiac impairment.</p><p>These high-risk patients require lower dosages and should be continuously monitored for early signs of alterations in vital functions.</p><p><em>Criteria for discharging patients from hospital </em></p><p>Patients who have received parenteral <strong>MODZAL&reg;</strong>&nbsp;should not leave hospital until at least 3 hours after the last injection and must be accompanied. Their attention should be drawn to the fact that they must not drive or operate machinery for at least 12 hours.</p><p><em>Tolerance</em></p><p>Some loss of efficacy has been observed when Midazolam has been used for long-term sedation in intensive care units (ICU).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Withdrawal symptoms </em></p><p>Since abrupt treatment discontinuation increases the risk of withdrawal symptoms, in particular after long-term sedation lasting &ge;2&ndash;3 days, gradual dose reduction is recommended. The following withdrawal symptoms may occur: headaches, muscle pains, anxiety, tension, restlessness, confusion, irritability, rebound insomnia, mood swings, hallucinations and convulsions.</p><p><em>Amnesia</em></p><p>Midazolam causes anterograde amnesia. Prolonged amnesia can present problems in outpatients who are due to go home after their procedure.</p><p><em>Paradoxical reactions </em></p><p>Paradoxical reactions such as agitation, involuntary movements (e.g. tonic/clonic convulsions and muscle tremor), hyperactivity, hostility, rage reaction, aggressiveness, paroxysmal excitement and assault, have been reported to occur with midazolam. These reactions may occur after the administration of high doses and/or rapid injection. Low susceptibility to such reactions in children and after high intravenous doses in the elderly.</p><p><em>Altered elimination of midazolam</em></p><p>Midazolam elimination may be altered in patients receiving drugs that inhibit or induce CYP3A4. The dose of midazolam may need to be adjusted accordingly.</p><p>Midazolam elimination may also be delayed in patients with hepatic impairment, low cardiac output, and in neonates.</p><p><em>Preterm infants </em></p><p>Due to the increased risk of apnea, extreme caution is mandatory when sedating preterm infants of gestational age &lt;36 weeks without an endotracheal tube in situ. Rapid injection must always be avoided in preterm infants of gestational age &lt;36 weeks. Respiratory rate and oxygen saturation must be closely monitored.</p><p><em>Infants under 6 months of age </em></p><p>In infants under 6 months of age, the risks of airway obstruction and hypoventilation are particularly high. Dose titration in small increments until clinical effect is achieved and careful monitoring of respiratory rate and oxygen saturation are therefore essential.</p><p><em>Concomitant use of alcohol/CNS depressants </em></p><p>The concomitant use of <strong>MODZAL&reg;</strong>&nbsp;and alcohol and/or CNS depressants should be avoided due to the risk of potentiation of the clinical effect of <strong>MODZAL&reg;</strong>, possibly severe sedation and clinically significant respiratory and/or cardiovascular depression.</p><p><em>History of alcohol, drug or prescription drug abuse </em></p><p><strong>MODZAL&reg;</strong>&nbsp;should not be used in patients with a history of alcohol or prescription drug abuse.</p><p><em>Miscellaneous </em></p><p>As with all substances having a central depressant and/or muscle relaxant effect, particular caution is mandatory when administering <strong>MODZAL&reg; </strong>to patients with myasthenia gravis.</p><p><em>Dependence</em></p><p>Physical dependence on midazolam may develop when <strong>MODZAL&reg;</strong>&nbsp;is used for long-term sedation. The risk of dependence increases with dose and treatment duration and is also increased in patients with a history of alcohol or prescription drug abuse.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacokinetic drug interactions</strong></p><p>Midazolam is almost exclusively metabolised by cytochrome P450 3A4 (CYP3A4). Inhibitors and inducers of CYP3A may increase or decrease plasma concentrations and hence the pharmacodynamic effects of midazolam. Apart from modulation of CYP3A activity, no other mechanism capable of causing pharmacokinetic drug interactions with midazolam has been demonstrated. Acute displacement from its plasma protein (albumin) binding sites may, however, at least theoretically, cause drug interactions with drugs reaching high serum concentrations, as for example (valproic acid).</p><p>No change due to midazolam is known in the pharmacokinetics of other drugs.</p><p>Close monitoring of clinical effects and vital signs is recommended when using midazolam, taking into account the fact that midazolam may have a more marked and sustained clinical effect if coadministered with a CYP3A inhibitor. Depending on the degree of CYP3A inhibition, marked reduction of the dose of midazolam may sometimes be possible. Conversely, when coadministering a CYP3A inducer, it may prove necessary to increased the dose of midazolam to achieve the desired effect.</p><p>In CYP3A induction and irreversible inhibition (known as mechanism-based inhibition), the effect of administering the CYP3A inhibitor on the pharmacokinetics of midazolam may last for several days, or even several weeks. Drugs that may cause mechanism-based inhibition of CYP3A include: antibacterials (e.g. clarithromycin, erythromycin, isoniazid), anti-HIV drugs (e.g. HIV protease inhibitors), antihypertensives (e.g. verapamil, diltiazem), steroid sex hormones and modulators of their receptors (e.g. gestoden, raloxifen) and various plant components (e.g. the bergamottin contained in grapefruit). Unlike the other substances causing mechanism-based inhibition, use of ethinylestradiol/norgestrel for oral contraception or grapefruit juice (200 ml) has caused no change of note in the plasma concentrations of intravenously administered midazolam.</p><p>The intensity of drug-induced CYP3A inhibition or induction is very variable. The antimycotic ketoconazole, a highly potent CYP3A inhibitor, multiply the plasma concentrations of intravenously administered midazolam approximately 5-fold. The tuberculostatic rifampicin is one of the most potent CYP3A inducers. When coadministered with midazolam, it reduces the plasma concentrations of intravenously administered midazolam by approximately 60%.</p><p>The route of midazolam administration also affects the degree of pharmacokinetic impact caused by CYP3A modulation:</p><p>a) The impact on plasma concentrations should be slighter when midazolam is administered intravenously rather than orally, since CYP3A modulation affects not only the systemic clearance of midazolam but also its bioavailability after oral administration;</p><p>b) There are no studies on the effects of CYP3A modulation on the pharmacokinetics of rectally or intramuscularly administered midazolam. Since the drug partially bypasses the liver when administered rectally, and since CYP3A is more weakly expressed in the colon than in the upper gastrointestinal tract, the impact of CYP3A modulation on plasma midazolam concentrations is likely to be weaker after rectal than after oral administration. Since the drug enters the systemic circulation directly after intramuscular injection, CYP3A modulation is likely to have the same effect as after intravenously administered midazolam.</p><p>C) Consistent with pharmacokinetic principles following the administration of a single intravenous dose of midazolam, the impact of CYP3A modulation on maximum clinical effect is weaker, whereas the duration of effect may be longer. However, after prolonged midazolam administration, both intensity and duration of effect are increased in the presence of CYP3A inhibition.</p><p>The following list provides examples of pharmacokinetic drug interactions with intravenously administered midazolam. It is important to note that each drug capable of modulating CYP3A in vitro or in vivo may in principle modify the plasma concentrations and hence effect of midazolam.</p><p><strong>Drugs that inhibit CYP3A4 </strong></p><p><em>Azole antifungals </em></p><p>- Ketoconazole multiply the plasma concentrations of intravenously administered midazolam 5-fold while approximately tripling its terminal half-life.</p><p>- Parenteral midazolam should only be coadministered with ketoconazole, a potent CYP3 inhibitor, in an intensive care unit (ICU) or similar setting to ensure close clinical monitoring in the event of respiratory depression and/or prolonged sedation. In particular, incremental dosing and dose adjustment should be considered when administering more than one intravenous dose of midazolam.</p><p>- Fluconazole and itraconazole both multiply the plasma concentrations of intravenously administered midazolam between two- and three-fold and prolong the terminal half-life 2.4-fold (itraconazole) and 1.5-fold (fluconazole).</p><p>- Posaconazole approximately double the plasma concentrations of intravenously administered midazolam.</p><p><em>Macrolide antibiotics </em></p><p>- Erythromycin multiply the plasma concentrations of intravenously administered midazolam approximately 1.6-fold to 2-fold and simultaneously prolonged the terminal half-life of midazolam 1.5-fold to 1.8-fold.</p><p>- Clarithromycin multiply the plasma concentrations of midazolam 2.5-fold while prolonging the terminal half-life 1.5-fold to 2-fold.</p><p>- Roxithromycin may have only a slight impact on intravenously administered midazolam.</p><p><em>HIV protease inhibitors </em></p><p>Saquinavir and other HIV protease inhibitors: when coadministered with ritonavir-boosted lopinavir, the plasma concentrations of intravenously administered midazolam will be multiplied 5.4-fold and the terminal half-life was correspondingly prolonged.</p><p>When coadministering midazolam with HIV protease inhibitors, treatment should comply with the description given in the above paragraph on ketoconazole in the Azole antifungals section.</p><p>No study on the in vivo interactions of intravenously administered midazolam with other protease inhibitors is available.</p><p><em>H2 histamine receptor antagonists </em></p><p>- Cimetidine increases plasma midazolam concentrations at steady state by 26%.</p><p>Calcium antagonists</p><p>- Diltiazem: A single dose of diltiazem increases the plasma concentrations of intravenously administered midazolam by approximately 25% and the terminal half-life by approximately 43%.</p><p><em>Miscellaneous drugs/herbal medicines </em></p><p>- Atorvastatin multiply the plasma concentrations of intravenously administered midazolam approximately 1.4-fold.</p><p><strong>Drugs that induce CYP3A </strong></p><p>Rifampicin 600 mg/day for 7 days reduced the concentrations of intravenously administered midazolam by approximately 60%. It decreases the terminal half-life by 50%&ndash;60%.</p><p><em>Herbal medicines and food </em></p><p>- Echinacea purpurea root extract reduced the plasma concentrations of intravenously administered midazolam by 20% and its half-life by approximately 42%.</p><p>- St John&rsquo;s wort reduced the plasma concentrations of midazolam by 20%&ndash;40%; it also shortened its terminal half-life by 15%&ndash;17%.</p><p><em>Acute displacement from plasma protein binding sites</em></p><p>Valproic acid: One publication has discussed the displacement of midazolam from its plasma protein binding sites by valproic acid as a possible mechanism of drug interaction. However, for methodological reasons the clinical significance of this study has been considered very limited. Given that the therapeutic plasma concentration of valproic acid is high, however, displacement of midazolam from its plasma protein binding sites by the administration of acute doses cannot be excluded, resulting in a more marked clinical effect of midazolam.</p><p><strong>Pharmacodynamic drug interactions </strong></p><p>Coadministration of midazolam with other sedatives/hypnotics (including alcohol) is likely to have an enhanced sedative or sleep-inducing effect. Examples of such substances include: opiates/opioids (used as analgesics, antitussives or replacement treatments), neuroleptics, other benzodiazepines used as anxiolytics or hypnotics, barbiturates, propofol, ketamine, etomidate, sedative antidepressants, antihistamines and centrally-acting antihypertensives. Midazolam decreases the minimum alveolar concentration of inhalational anesthetics.</p><p>A more marked effect on sedation, respiration and hemodynamics may occur when coadministering midazolam with centrally-acting antidepressants, including alcohol. Appropriate monitoring of vital functions should be performed for this reason. Alcohol must not be used in any form after midazolam administration.</p><p>It has been shown spinal anesthesia may enhance the sedative effect of intravenously administered midazolam. In such cases the dose of midazolam can be reduced. Intramuscular administration of lidocaine and bupivacaine also reduces the dose of intravenously administered midazolam required for sedation.</p><p>Drugs that enhance attention and memory, such as physostigmine, an acetylcholinesterase inhibitor, suppress the sleep-inducing effect of midazolam. Similarly, 250 mg caffeine also partially inhibits the sedative effect of midazolam.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There is clear evidence of risk to the human fetus from benzodiazepine administration during pregnancy.</p><p><strong>MODZAL&reg;</strong>&nbsp;must therefore not be used during pregnancy, except if absolutely necessary.</p><p>Caution is mandatory when administering benzodiazepines in late pregnancy and during labour, given that irregularities in the heart rate and hypotension may occur in the fetus, while a reduced desire to suck, respiratory depression, reduced activity, floppy infant syndrome, withdrawal symptoms and hypothermia may occur in the neonate.</p><p>Lactation</p><p>Midazolam passes in low quantities into breast milk. Nursing mothers should be advised to discontinue breastfeeding for 24 hours following administration of midazolam.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sedation, amnesia, concentration difficulties and muscle dysfunction impair the ability to drive and use machines. Before receiving <strong>MODZAL&reg;</strong>, patients should be warned not to drive or use machines until the effect of the drug has fully worn off, but in no case less than 12 hours after the last injection. The physician should decide when the patient may resume these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects have been observed in very rare cases after midazolam injection.</p><p><strong>Immune system disorders</strong></p><p>General hypersensitivity reactions (skin reactions, cardiovascular reactions, bronchospasm), angioedema anaphylactic shock.</p><p><strong>Psychiatric disorders </strong></p><p>Mental confusion, hallucinations, nervousness, euphoria, decreased attention, fatigue.</p><p>Paradoxical reactions such as agitation, involuntary movements (such as tonic/clonic movements and muscle tremor), hyperactivity, hostility, rage reactions, aggressiveness, paroxysmal excitement and assault have been reported, in particular among children and the elderly.</p><p><strong>Dependence</strong></p><p>Even at therapeutic doses, use of <strong>MODZAL&reg;</strong>&nbsp; may lead to physical dependence. After prolonged intravenous administration, withdrawal symptoms, including withdrawal seizures, may occur after discontinuing treatment, in particular if discontinuation is abrupt.</p><p><strong>Nervous system disorders </strong></p><p>Prolonged sedation, decreased attention, headache, dizziness, ataxia, postoperative sedation, and anterograde amnesia, the duration of which is directly related to the administered dose. Anterograde amnesia may still persist after the end of the procedure; and prolonged amnesia has been reported in isolated cases.</p><p>Seizures have been reported in preterm infants and neonates.</p><p><strong>Cardiac disorders </strong></p><p>Cardiac arrest, bradycardia.</p><p>Severe cardiorespiratory adverse events have occurred in rare cases. These have included: cardiac arrest, hypotension, bradycardia and vasodilatory effects. The probability of life-threatening events is increased in adults over 60 years of age, in patients with pre-existing respiratory disease and in those with heart failure, above all when injection is too rapid or when a high dose is administered .</p><p><strong>Respiratory disorders</strong></p><p>Severe cardiorespiratory adverse events have occurred in rare cases. These have included: respiratory depression, apnea, respiratory arrest, dyspnea and laryngospasm. Life-threatening incidents are more likely to occur in adults over 60 years of age and those with pre-existing respiratory or cardiac insufficiency, above all when injection is too rapid or when a high dose is administered .Hiccup.</p><p><strong>Gastrointestinal disorders </strong></p><p>Nausea, vomiting, constipation, dry mouth.</p><p><strong>Skin disorders</strong></p><p>Rash, urticaria, pruritus.</p><p><strong>Injection site reactions </strong></p><p>Erythema and pain at the injection site, thrombophlebitis, thrombosis.</p><p><strong>Injury, poisoning and procedural complications </strong></p><p>Increased falls and fractures have been observed in benzodiazepine users. The risk is increased by the concomitant use or ingestion of sedatives (including alcoholic beverages) and in elderly patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms </strong></p><p>Benzodiazepines generally cause confusion, ataxia, dysarthria and nystagmus. <strong>MODZAL&reg;</strong>&nbsp;overdose is seldom life-threatening if the drug is taken alone, but may lead to areflexia, apnea, hypotension, cardiorespiratory depression and, in rare cases, to coma. If coma occurs, it generally lasts a few hours but it may be prolonged and cyclical in elderly patients. Benzodiazepine respiratory depressant effects are more serious in patients with respiratory disease.</p><p>Benzodiazepines potentiate the effect of CNS depressants, including alcohol.</p><p><strong>Treatment </strong></p><p>Monitor the patient&rsquo;s vital signs and institute supportive measures as indicated by the patient&rsquo;s clinical state. In particular, patients may require symptomatic treatment for cardiorespiratory effects or central nervous system effects.</p><p>The use of (flumazenil), a benzodiazepine antagonist, should be considered if central nervous system depression is severe. It should only be administered under closely monitored conditions. Since it has a short half-life (about 1 hour), patients receiving flumazenil must be monitored when its effect wears off. Flumazenil is to be used with extreme caution in conjunction with drugs that reduce the seizure threshold (e.g. tricyclic antidepressants).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: N05CD08</p><p><strong>Mechanism of action</strong></p><p>Midazolam, the active substance in <strong>MODZAL&reg;</strong>, is an imidazobenzodiazepine. The free base is lipophilic and weakly water-soluble.</p><p>Thanks to the basic nitrogen in position 2 of the imidazobenzodiazepine ring system, the active substance in <strong>MODZAL&reg;</strong>&nbsp;is able to form water-soluble salts with acids that produce a stable injectable solution.</p><p>The pharmacological characteristics of Midazolam are rapid onset of effect and, thanks to rapid metabolic transformation, short duration of effect. The low toxicity of Midazolam confers a wide therapeutic safety margin.</p><p>Midazolam has a very rapid sedative and sleep-inducing effect. It also has an anxiolytic, anticonvulsant and muscle-relaxant effect.</p><p>Short-lasting anterograde amnesia (patients do not remember events that occur during the phase of maximum drug activity) follows intramuscular or intravenous administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption </strong></p><p><strong>Absorption after intramuscular injection </strong></p><p>Midazolam absorption from muscle tissue is rapid and complete. Peak plasma concentrations are reached within 30 minutes. Absolute bioavailability exceeds 90%.</p><p><em>Absorption after rectal administration </em></p><p>Midazolam absorption after rectal administration is rapid. Peak plasma concentrations are reached within approximately 30 minutes. Absolute bioavailability is approximately 50%.</p><p><strong>Distribution </strong></p><p>When Midazolam is administered intravenously, the plasma concentration time curve shows one or two distinct phases of distribution. The volume of distribution at steady state is 0.7&ndash;1.2 l/kg. Midazolam is 96%&ndash;98% bound to plasma protein. Protein binding is due mainly to albumin. Midazolam passes slowly but in insignificant amounts into cerebrospinal fluid.</p><p>In humans, midazolam has been shown to cross the placental barrier slowly and to enter the fetal circulation. Half to one hour after oral dosing with 15 mg, the ratio between the fetal serum concentration (cord blood) and maternal serum concentration was 0.6&ndash;1.0. The elimination half-life of midazolam and its main metabolites in neonates is approximately 6.3 hours. In humans, small quantities of midazolam have also been demonstrated in breast milk.</p><p><strong>Metabolism </strong></p><p>Midazolam is almost entirely eliminated by biotransformation. Less than 1% of the dose is recovered in urine as unchanged drug. Midazolam is hydroxylated by the cytochrome P450 3A4 isoenzyme. The major urinary and plasma metabolite is &alpha;-hydroxymidazolam. Plasma concentrations of &alpha;-hydroxymidazolam are 12% those of the parent compound. The fraction of the dose extracted by the liver has been estimated to be 30%&ndash;60%. The elimination half-life of the metabolite is less than 1 hour; &alpha;-hydroxymidazolam is pharmacologically active, but contributes minimally (approximately 10%) to the effect of intravenously administered midazolam. There is no evidence of genetic polymorphism in oxidative midazolam metabolism.</p><p><strong>Elimination </strong></p><p>the elimination half-life is 1.5&ndash;3.5 hours. Plasma clearance is in the range 300&ndash;500 ml/min; 60%&ndash;80% of the dose is eliminated in the urine as the &alpha;-hydroxymidazolam glucuronide conjugate. Less than 1% of the dose is recovered in urine as unchanged drug. The elimination half-life of the metabolite is under 1 hour. When midazolam is given by intravenous infusion, its elimination kinetics do not differ from those observed following bolus injection.</p><p><strong>Pharmacokinetics in special patient populations </strong></p><p><em>Elderly patients </em></p><p>In persons over 60 years of age, the elimination half-life may be quadrupled.</p><p><em>Children</em></p><p>In children, the rate of midazolam absorption after rectal administration is similar to that in adults, but bioavailability is lower (5%&ndash;18%). However, the elimination half-life (t&frac12;) after intravenous and rectal administration in children aged 3&ndash;10 years is shorter than in adults (1.0&ndash;1.5 h). The difference is consistent with increased metabolic clearance in children.</p><p><em>Neonates </em></p><p>In preterm infants and neonates, the average elimination half-life is 6&ndash;12 h, probably due to liver immaturity; clearance is reduced.</p><p><em>Overweight patients</em></p><p>Mean half-life is longer in overweight than in normal-weight patients (8.4 vs 2.7 h). This is due to an increase of approximately 50% in the volume of distribution corrected for total body weight. Clearance does not differ significantly in overweight compared to normal-weight patients.</p><p><em>Patients with hepatic impairment </em></p><p>In cirrhotic patients, the elimination half-life may be longer and clearance lower than in healthy People.</p><p><em>Patients with renal impairment </em></p><p>In patients with chronic renal failure, the elimination half-life is similar to that in healthy People. It has, however, been shown that &alpha;-hydroxymidazolam accumulates and could enhance the clinical effect of midazolam, which could result in prolonged sedation.</p><p><em>Critically ill patients </em></p><p>The elimination half-life of midazolam is prolonged in critically ill patients.</p><p><em>Patients with heart failure </em></p><p>In patients with heart failure, the elimination half-life is longer than in healthy People.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Mutagenic and carcinogenic potential </strong></p><p>Liver and thyroid tumours were observed in long-term studies in mice and rats. The consensus view is that these data cannot be extrapolated to humans.</p><p>The results of in vitro and in vivo genotoxicity studies show that mutagenic, clastogenic and aneugenic effects are unlikely with the use of midazolam.</p><p><strong>Reproductive toxicology </strong></p><p>Like all benzodiazepines, midazolam crosses the placental barrier.</p><p><strong>Teratogenicity </strong></p><p>Studies of midazolam in rats and mice revealed no evidence of teratogenicity.</p><p>However, signs of behavioural disturbance were observed in the offspring of females exposed to benzodiazepines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride, Edetate Disodium, Hydrochloric acid, Sodium Hydroxide, Water for Injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Midazolam precipitates in sodium bicarbonate.</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf-life before first opening
2 years 
Shelf-life after first opening
Midazolam 5 mg/ml solution for injection is intended for single use. Unused solution is to be disposed of.
Shelf-life after dilution
Chemical and physical in-use stability of the dilutions (see section 6.6) has been demonstrated for 72 hours at 25°C.
From the microbiological point of view, the dilutions should be used immediately.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C, protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Class A vial 3ml with Rubber stopper 13 mm</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compatibility with infusion solutions: <strong>MODZAL&reg;</strong>&nbsp;solution can be diluted in 0.9% sodium chloride, 5% glucose, 5% in a ratio of 15 mg midazolam per 100&ndash;1000 ml infusion solution. These solutions remain physically and chemically stable for 24 hours at room temperature (or for 3 days at 5&deg;C).</p><p><strong>MODZAL&reg;</strong>&nbsp;solution must not be diluted in glucose solution with 6% macrodex nor mixed with alkaline solutions for injection.</p><p><strong>MODZAL&reg;</strong>&nbsp;vials are for single use only. Discard all unused residual product.</p><p>Inspect the solution before use. Only use clear solutions devoid of particulate matter.</p><p>Rectal administration</p><p>For rectal administration of the vials solution, a plastic applicator (rectal applicator) is fitted onto the syringe tip. If the administration volume is too low, water can be added to a total volume of 10 ml.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>